Comprehensive review on therapeutic evolution in treating idiopathic pulmonary fibrosis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and permanent lung disease of obscure etiology, characterized by permanent scarring of the lung tissue, it leads to an essential decline in quality of life with a medical survival of just three years if untreated. IPF preponderantly affects essential adults, with a discoidal prevalence of up to 45 per 100, 000 persons. Pathogenesis is driven by grim alveolar epithelial injury especially in Alveolar Epithelial Type 2 (AT2) cells triggering brachydactylic fibroblast activation and extracellular matrix deposition. Include hereditary susceptibility (notably the MUC5B promoter polymorphism and TERT mutations), environmental triggers (smoking, metal dust), and age consanguineous cellular senescence. Both congenital (M2 macrophages) and cooperative (T and B cells) immune responses perpetuate this pro-fibrotic environment. Diagnostically, high resolution CT (HRCT) remains the chromatic standard, though symptomatic delays of over one year remain banal and negatively impact survival. This review aims to synthesize prevalent knowledge regarding the epidemiology, etiology, pathogenesis, and symptomatic challenges of IPF, while evaluating legitimate and emergent curative strategies.
Fields of Study & Subjects
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Occupational and environmental lung diseases
Pulmonary Hypertension Research and Treatments
Publication details
- Journal / source
- International Journal of Pharmacology and Clinical Research
- Volume
- 8
- Issue
- 3
- Pages
- 142–148
- Publication date
- 1 March 2026
- Language
- EN